Technetium-99m- Arg-Arg-Leu(g2), a modified peptide probe targeted to neovascularization in molecular tumor imaging

Journal of B.U.ON.

Volumn 18, Issue 4, 2013, Pages 1074-1081

  Lu, Xia ^a,b   Zhao, Lingzhou ^a   Xue, Tian ^a   Zhang, Huabei ^a  

^a BEIJING NORMAL UNIVERSITY   (China)

^b Beijing Aerospace Hospitals   (China)

Author keywords

99mTc; Molecular imaging; Peptide probe; RRL (g2); Tumor angiogenesis

Indexed keywords

GLYCYLGLYCYLALANYLGLYCYLSERYLLYSYLCYSTEINYLGLYCYLARGINYLARGINYLLEUCYLGLYCYLCYSTEINAMIDE FITC; GLYCYLGLYCYLALANYLGLYCYLSERYLLYSYLCYSTEINYLGLYCYLARGINYLARGINYLLEUCYLGLYCYLCYSTEINAMIDE TC 99M; GLYCYLGLYCYLALANYLGLYCYLSERYLLYSYLCYSTEINYLGLYCYLGLYCYLGLYCYLGLYCYLGLYCYLCYSTEINAMIDE FITC; GLYCYLGLYCYLALANYLGLYCYLSERYLLYSYLCYSTEINYLGLYCYLGLYCYLGLYCYLGLYCYLGLYCYLCYSTEINAMIDE TC 99M; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; BINDING ASSAY; CANCER TISSUE; CELL ADHESION; CELL ADHESION ASSAY; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG PURIFICATION; DRUG SYNTHESIS; ELECTROSPRAY MASS SPECTROMETRY; ENDOTHELIUM CELL; GLIOBLASTOMA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; ISOTOPE LABELING; MALE; MOLECULAR DOCKING; MOLECULAR IMAGING; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; RADIOCHEMISTRY;

ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; COMPUTER-AIDED DESIGN; ENDOTHELIAL CELLS; GLIOBLASTOMA; HALF-LIFE; HUMANS; MICE; MICE, NUDE; MOLECULAR DOCKING SIMULATION; MOLECULAR IMAGING; NEOVASCULARIZATION, PATHOLOGIC; OLIGOPEPTIDES; ORGANOTECHNETIUM COMPOUNDS; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84893079244     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Michael P, Iram H. Mechanisms of normal and tumor-derived angiogenesis. Am J Physiol Cell Physiol 2002;282:C947-C970.
2. Mankoff DA. A definition of molecular imaging. J Nucl Med 2007;48:18N-21N.
3. Brown CK, Modzelewski RA, Johnson CS, Wong MK. A Novel Approach for the Identification of Unique Tumor Vasculature Binding Peptides Using an E.coli Peptide Display Library. Ann Surg Oncol 2000;7:743-749.
4. Yu MM, Wang RF, Yan P et al. Design, synthesis and iodination of an Arg-Arg-Leu peptide for potential use as an imaging agent for human prostate carcinoma. J Label Compd Radiopharm 2008;51:374-378.
5. Lu X, Yan P, Wang RF et al. The further study on radioiodinated peptide Arg-Arg-Leu targeted to neovascularization as well as tumor cells in molecular tumor imaging. J Radioanalyt Nucl Chem 2011;290:623-630,
6. Waerzeggers Y, Monfared P, Viel T et al. Specific biomarkers of receptors, pathways of inhibition and targeted therapies :pre-clinical developments. Br J Radiol 2011;84:S 168-S178.
7. Lu X, Yan P, RF et al. Use of Radioiodinated Peptide Arg- Arg-Leu Targeted to Neovascularization as well as Tumor Cells in Molecular Tumor Imaging. Chin J Cancer Res 2012;24 .52-59.
8. Nyberg P, Xie L, Kalluri R. Endogenous inhibitors of n angiogenesis. Cancer Res 2005;65:3967-3979.
9. Buscombe JR, Wong B. PET a tool for assessing the in vivo tumour cell and its microenvironment? Br Med Bull 2013;105 :157-167.
10. Ferrara N. VEGF and the quest for tumor angiogenesis factors. Nat Rev Cancer 2002;2 :795-803. (Pubitemid 37328914)
11. Cai W, Chen X. Anti-angiogenic cancer therapy based on integrin avb3 antagonism. Anticancer Agents Med Chem 2006;6:407-428.
12. Gwyther SJ. New imaging techniques in cancer management. Ann Oncol 2005,:16.:ii63-ii70.
13. Rudin M, Weissleder R. Molecular imaging in drug discovery and development. Nat Rev Drug Discov 2003;2:123-131. (Pubitemid 37361644)
14. Jain RK. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res 1990;50:814-819.
15. Willman JL, Murugan P, Chen K et al. US Imaging of tumor angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in mice. Radiology 2008;245:508-518.
16. Fani M, Psimadas D, Zikos C et al. Comparative evaluation of linear and cyclic 99mTc-RGD peptides for targeting of integrins in tumor angiogenesis. Anticancer Res 2006;26:431-434 (Pubitemid 43206109)